Dyne Therapeutics (NASDAQ:DYN) Sets New 1-Year High Following Analyst Upgrade

Dyne Therapeutics, Inc. (NASDAQ:DYNGet Free Report) reached a new 52-week high during trading on Wednesday after JPMorgan Chase & Co. raised their price target on the stock from $39.00 to $43.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Dyne Therapeutics traded as high as $37.49 and last traded at $37.15, with a volume of 16727 shares changing hands. The stock had previously closed at $37.21.

Other equities research analysts also recently issued reports about the company. HC Wainwright increased their price target on Dyne Therapeutics from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, May 20th. Oppenheimer restated an “outperform” rating and issued a $47.00 price target on shares of Dyne Therapeutics in a report on Monday, May 6th. Chardan Capital increased their price target on Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, May 21st. Morgan Stanley initiated coverage on Dyne Therapeutics in a report on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 price target for the company. Finally, Jefferies Financial Group increased their price objective on Dyne Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, May 20th. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.11.

Read Our Latest Stock Analysis on Dyne Therapeutics

Insider Buying and Selling

In other Dyne Therapeutics news, COO Susanna Gatti High sold 2,738 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total transaction of $77,403.26. Following the transaction, the chief operating officer now owns 154,062 shares in the company, valued at approximately $4,355,332.74. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Dyne Therapeutics news, COO Susanna Gatti High sold 2,738 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total transaction of $77,403.26. Following the transaction, the chief operating officer now owns 154,062 shares in the company, valued at approximately $4,355,332.74. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Oxana Beskrovnaya sold 2,705 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total value of $76,470.35. Following the transaction, the insider now owns 149,647 shares in the company, valued at approximately $4,230,520.69. The disclosure for this sale can be found here. In the last ninety days, insiders sold 202,133 shares of company stock valued at $6,500,387. Insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Wetzel Investment Advisors Inc. acquired a new stake in shares of Dyne Therapeutics during the 1st quarter valued at $28,000. Ameritas Investment Partners Inc. boosted its holdings in shares of Dyne Therapeutics by 28.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after acquiring an additional 1,291 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Dyne Therapeutics by 355.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after acquiring an additional 5,541 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Dyne Therapeutics during the 1st quarter valued at $214,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Dyne Therapeutics during the 4th quarter valued at $172,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Performance

The company has a market cap of $3.46 billion, a price-to-earnings ratio of -9.96 and a beta of 1.07. The company has a fifty day moving average of $31.68 and a two-hundred day moving average of $25.91.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last announced its earnings results on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, hitting the consensus estimate of ($0.81). Equities analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

See Also

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.